Loading...
XNAS
PCRX
Market cap1.09bUSD
Dec 05, Last price  
23.99USD
1D
0.04%
1Q
-9.30%
Jan 2017
-25.73%
IPO
241.25%
Name

Pacira Biosciences Inc

Chart & Performance

D1W1MN
XNAS:PCRX chart
P/E
P/S
1.56
EPS
Div Yield, %
Shrs. gr., 5y
2.18%
Rev. gr., 5y
10.73%
Revenues
701m
+3.85%
13,925,00015,006,00014,562,00015,689,00039,084,00085,551,000197,668,000248,997,000276,371,000286,630,000337,277,000421,026,000420,830,000541,533,000666,823,000674,978,000700,966,000
Net income
-100m
L
-41,862,000-31,707,000-27,149,000-43,328,000-52,281,000-63,909,000-13,716,0001,856,000-37,949,000-42,611,000-471,000-11,016,000145,523,00041,980,00015,909,00041,955,000-99,560,000
CFO
189m
+22.46%
-29,189,000-20,838,000-24,880,000-31,000,000-70,130,000-43,216,00025,469,00028,996,00033,453,00017,785,00048,870,00070,520,00077,032,000125,717,000145,274,000154,649,000189,389,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
IPO date
Feb 03, 2011
Employees
715
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT